Becton, Dickinson and Company (NYSE:BDX) Q3 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Greg Rodetis - Senior Vice President, Treasurer & Head of Investor Relations Tom Polen - Chairman, Chief Executive Officer & President Chris DelOrefice - Executive Vice President & Chief Financial Officer Mike Garrison - President of the Medical Segment Conference Call Participants Robbie Marcus - JPMorgan Travis Steed - Bank of America David Roman - Goldman Sachs Patrick Wood - Morgan St ...

Becton Dickinson (BDX) reported $4.99 billion in revenue for the quarter ended June 2024, representing a yearover-year increase of 2.3%. EPS of $3.50 for the same period compares to $2.96 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $5.07 billion, representing a surprise of -1.57%. The company delivered an EPS surprise of +5.74%, with the consensus EPS estimate being $3.31. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

Becton Dickinson (BDX) came out with quarterly earnings of $3.50 per share, beating the Zacks Consensus Estimate of $3.31 per share. This compares to earnings of $2.96 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 5.74%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $2.96 per share when it actually produced earnings of $3.17, delivering a surprise of 7.09%. Over the last four qu ...

Exhibit 99.1 Contacts: Investors: Adam Reiffe, Sr. Director, Investor Relations - 201-847-6927 Media: Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD Reports Third Quarter Fiscal 2024 Financial Results Strong Margin Execution Drives Performance in Quarter • Revenue of $5.0 billion as reported, adjusted revenue of $5.1 billion, driven by strong organic revenue growth • GAAP and adjusted diluted EPS of $1.68 and $3.50 grew 23.5% and 18.2%, respectively • Year-to-date Cash from Continuing Operations g ...

Strong Margin Execution Drives Performance in Quarter Revenue of $5.0 billion as reported, adjusted revenue of $5.1 billion, driven by strong organic revenue growth GAAP and adjusted diluted EPS of $1.68 and $3.50 grew 23.5% and 18.2%, respectively Year-to-date Cash from Continuing Operations grew 60% to $2.7 billion and Free Cash Flow grew over 100% to $2.2 billion, increasing $1.0 billion and $1.2 billion since the prior year, respectively The company updated its fiscal 2024 GAAP revenue growth guidance t ...

Let's check out the factors that have shaped BDX's performance prior to this announcement. In April, BD's Biosciences business unit announced the global commercial release of the three- and four-laser additions to the BD FACSDiscover S8 Cell Sorter family, which complement the five-laser instrument launched last year. In February, BD announced a strategic partnership with Camtech Health to increase access to cervical cancer screening in Singapore through the country's first-ever program to offer at-home sel ...

Collaboration on Flow Cytometry-Based Companion Diagnostics to Advance Personalized Health Care FRANKLIN LAKES, N.J. and SECAUCUS, N.J., July 25, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a global collaboration agreement to develop, manufacture and commercialize flow cytometry-based companion diagnostics (CDx) intended to help select the best ...

FRANKLIN LAKES, N.J., July 23, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $0.95 per common share, payable on September 30, 2024 to holders of record on September 9, 2024. The indicated annual dividend rate is $3.80 per share. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving ...

Becton Dickinson (BDX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. The power of a ...

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Becton Dickinson (BDX) or Merit Medical (MMSI) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate ...